CompaniesA-sharesNews brief

China Resources Double Crane Gets NMPA Drug Certificate for Lomustine Capsules

Published: 1 September 2026 at 17:10Updated: 1 September 2026 at 17:17By 24TopNews Editorial Desk

China Resources Double Crane Pharmaceutical announced on September 1 that lomustine capsules, filed by the company as the domestic agent, have received a Drug Registration Certificate from the National Medical Products Administration. Lomustine capsules are indicated for pediatric and adult patients with primary malignant brain tumors following surgery and/or radiotherapy.